CIK 0001590877
- Non-accelerated filer
- Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 471851754
- Phone
- +1 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- 4 Grant or award Director acquired 4,790 shares (grant or award)
- 4 Grant or award Director acquired 4,790 shares (grant or award)
- 4 Grant or award Director acquired 4,790 shares (grant or award)
- 4 Grant or award Director acquired 4,790 shares (grant or award)
- 4 Grant or award Director acquired 4,790 shares (grant or award)
- 4 Grant or award Director acquired 4,790 shares (grant or award)
- 4 Grant or award Director acquired 4,790 shares (grant or award)
- 4 Grant or award Director acquired 4,790 shares (grant or award)
- 4 Planned sale President and CEO sold 15,000 shares at $15.81 ($237,222)
- 4 Planned sale President and CEO sold 15,000 shares at $18.19 ($272,871)
- 4 Exercise or conversion Chief Financial Officer acquired 20,041 shares (option exercise)
- 4 Planned sale President and CEO sold 15,000 shares at $21.86 ($327,942)
- 4 Planned sale Chief Medical Officer sold 12,878 shares at $28.36 ($365,220)
- 4 Planned sale President and CEO sold 15,000 shares at an average $16.76 ($251,349)
- 4 Planned sale President and CEO sold 45,000 shares at $15.18 ($682,992)
- 4 Shares withheld for taxes Chief Oper. & Tech. Officer gave up 8,120 shares (to pay taxes)
- 4 Planned sale Chief Medical Officer sold 17,237 shares at $17.39 ($299,789)
- 4 Shares withheld for taxes Chief Scientific Officer gave up 8,410 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Financial Officer gave up 4,534 shares (to pay taxes)
- 4 Shares withheld for taxes President and CEO gave up 11,357 shares (to pay taxes)
Page 5 of 22 · 435 filings